Breaking AI & Tech News Analyzed

A recent conversation with a guest at an academic function brought to light the public's desire for a simple, all-encompassing test for cancer. The guest, intrigued by the speaker's profession as an oncologist, inquired about the existence of an 'everything' test for cancer. The speaker's response was clear: no such test exists.The quest for early cancer detection is a significant goal in cancer medicine, with the aim of identifying the disease before it metastasizes and ensuring a cure. One company, Grail, launched a blood test called Galleri, which claims to detect a 'signal' shared by more than 50 types of cancer. This signal is identified through circulating DNA, minute fragments of cancer DNA present in the bloodstream.The Galleri test was marketed as a screening tool, with results indicating either a cancer signal detected or no cancer signal detected. However, the test failed to meet its primary endpoint in a large-scale trial conducted with the NHS, which aimed to determine if the test could reduce late-stage cancer diagnoses. Despite the company's claims of 'strong' results, the trial did not demonstrate a significant reduction in late-stage cancer diagnoses.The failure of the Galleri test highlights a crucial distinction between detecting more cancers and saving lives. Detecting cancer at an early stage does not necessarily translate to less invasive treatments or prolonged survival. Moreover, some cancers detected through screening may never have posed a lethal threat, leading to unnecessary interventions.For now, there is no blood test or total body scan that saves lives. Instead, the focus should be on modifying cancer risk factors, such as reducing processed foods, curbing alcohol consumption, quitting smoking, and engaging in regular exercise. These evidence-based approaches may not be as flashy as a single 'everything' test, but they have a proven impact on public health.

The recent sanctions imposed by the Trump administration against a UN human rights expert have raised alarm bells about the state of free speech and the ability to criticize government policies without fear of retribution. The expert, Francesca Albanese, was appointed by the United Nations to monitor human rights in occupied Palestine. Her offense was recommending that the International Criminal Court (ICC) issue arrest warrants for Israeli Prime Minister Benjamin Netanyahu and Defense Minister Yoav Gallant for war crimes committed in Gaza. The sanctions, which amount to a "civil death," have effectively silenced Albanese, preventing her from opening a bank account, selling her Washington DC house, or drawing a salary from American universities that employed her. This has had a ripple effect, causing fear among faculty and students on campuses who are now hesitant to criticize Israel's human rights record. The executive order signed by Trump threatens to criminally prosecute anyone who provides Albanese or other designated figures with "funds, goods, or services." This vague language has led to a Maine university canceling an academic conference where Albanese was to make an unpaid appearance via Zoom. The authors of the article, a group of North American university professors and human rights lawyers, argue that this has created a chilling effect on free speech, deterring people from expressing their views for fear of facing sanctions or arrest. They have filed a "friend-of-the-court" brief in support of a lawsuit filed by Albanese's husband and daughter against Trump's unconstitutional sanctions. The targeting of Albanese has significant implications beyond those focused on Israel's human rights record. It should concern anyone who believes in free speech and the ability to challenge those in power without fear of retribution. When a government claims the authority to police ideas, everyone's liberty is on the line.